{
    "Trade/Device Name(s)": [
        "CRYOcheck Factor VIII Deficient Plasma with VWF"
    ],
    "Submitter Information": "Precision BioLogic Inc.",
    "510(k) Number": "K222831",
    "Predicate Device Reference 510(k) Number(s)": [
        "K110237"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GJT"
    ],
    "Summary Letter Date": "September 13, 2023",
    "Summary Letter Received Date": "May 19, 2023",
    "Submission Date": "May 19, 2023",
    "Regulation Number(s)": [
        "21 CFR 864.7290"
    ],
    "Regulation Name(s)": [
        "Factor Deficiency Test"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Factor VIII"
    ],
    "Specimen Type(s)": [
        "Human plasma"
    ],
    "Specimen Container(s)": [
        "Frozen aliquot vial (1.0 mL or 1.5 mL)"
    ],
    "Instrument(s)/Platform(s)": [
        "IL ACL TOP Series",
        "IL ACL TOP 700 CTS",
        "IL ACL TOP 500",
        "IL ACL TOP 750 CTS",
        "IL ACL TOP 300"
    ],
    "Method(s)/Technology(ies)": [
        "Activated Partial Thromboplastin Time (APTT) assay",
        "Clot-based assay"
    ],
    "Methodologies": [
        "Quantitative clotting assay",
        "Modified APTT",
        "Deficient plasma correction"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Deficient substrate"
    ],
    "Document Summary": "FDA 510(k) summary for CRYOcheck Factor VIII Deficient Plasma with VWF as a reagent for quantitative FVIII determination in citrated plasma using APTT-based assays",
    "Indications for Use Summary": "For clinical laboratory use as a deficient substrate in quantitative determination of Factor VIII activity in 3.2% citrated human plasma via APTT assay; used to identify Factor VIII deficiency and as an aid in management of hemophilia A for individuals aged 2 years and older, for in vitro diagnostic use.",
    "fda_folder": "Hematology"
}